What was the primary intervention tested in the Breast Cancer Prevention Trial for high-risk women?

What was the primary intervention tested in the Breast Cancer Prevention Trial for high-risk women?

• A. Raloxifene
• B. Letrozole
• C. Tamoxifen
• D. Exemestane

Answer: (C)

In the Breast Cancer Prevention Trial, the primary intervention tested for high-risk women was Tamoxifen. This selective estrogen receptor modulator (SERM) was chosen due to its established role in reducing the risk of breast cancer in women who are at high risk due to factors such as family history, genetic predispositions, or previous benign breast disease. The trial aimed to assess the efficacy and safety of Tamoxifen in preventing breast cancer development. Tamoxifen works by binding to estrogen receptors in breast tissue, thereby blocking estrogen's ability to promote the growth of estrogen-sensitive tumors. This mechanism is particularly beneficial for women at high risk, as it addresses the hormonal factors that contribute to the development of breast cancer. The findings from the trial demonstrated that Tamoxifen significantly reduced the incidence of breast cancer among participants, thus solidifying its role in preventive strategies for high-risk populations. While the other options—Raloxifene, Letrozole, and Exemestane—are also medications used in breast cancer treatment or prevention, they were either not the focus of this specific trial or were evaluated in different contexts or populations. Raloxifene, for example, has been studied for preventing osteoporosis and has some research regarding breast cancer prevention but was not

In the Breast Cancer Prevention Trial, the primary intervention tested for high-risk women was Tamoxifen. This selective estrogen receptor modulator (SERM) was chosen due to its established role in reducing the risk of breast cancer in women who are at high risk due to factors such as family history, genetic predispositions, or previous benign breast disease. The trial aimed to assess the efficacy and safety of Tamoxifen in preventing breast cancer development.

Tamoxifen works by binding to estrogen receptors in breast tissue, thereby blocking estrogen's ability to promote the growth of estrogen-sensitive tumors. This mechanism is particularly beneficial for women at high risk, as it addresses the hormonal factors that contribute to the development of breast cancer. The findings from the trial demonstrated that Tamoxifen significantly reduced the incidence of breast cancer among participants, thus solidifying its role in preventive strategies for high-risk populations.

While the other options—Raloxifene, Letrozole, and Exemestane—are also medications used in breast cancer treatment or prevention, they were either not the focus of this specific trial or were evaluated in different contexts or populations. Raloxifene, for example, has been studied for preventing osteoporosis and has some research regarding breast cancer prevention but was not